PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma

Purpose: Mutation of TP53 gene is a hallmark of head and neck squamous cell carcinoma (HNSCC) not yet exploited therapeutically. TP53 mutation frequently leads to the synthesis of mutant p53 proteins with gain-of-function activity, associated with radioresistance and high incidence of local recurrences in HNSCC. Experimental Design: Mutant p53–associated functions were investigated through gene set enrichment analysis in the Cancer Genome Atlas cohort of HNSCC and in a panel of 22 HNSCC cell lines. Mutant p53–dependent transcripts were analyzed in HNSCC cell line Cal27, carrying mutant p53H193L; FaDu, carrying p53R248L; and Detroit 562, carrying p53R175H. Drugs impinging on mutant p53-MYC–dependent signature were identified interrogating Connectivity Map (https://clue.io) derived from the Library of Integrated Network–based Cellular Signatures (LINCS) database (http://lincs.hms.harvard.edu/) and analyzed in HNSCC cell lines and patient-derived xenografts (PDX) models. Results: We identified a signature of transcripts directly controlled by gain-of-function mutant p53 protein and prognostic in HNSCC, which is highly enriched of MYC targets. Specifically, both in PDX and cell lines of HNSCC treated with the PI3Kα-selective inhibitor BYL719 (alpelisib) the downregulation of mutant p53/MYC-dependent signature correlates with response to this compound. Mechanistically, mutant p53 favors the binding of MYC to its target promoters and enhances MYC protein stability. Treatment with BYL719 disrupts the interaction of MYC, mutant p53, and YAP proteins with MYC target promoters. Of note, depletion of MYC, mutant p53, or YAP potentiates the effectiveness of BYL719 treatment. Conclusions: Collectively, the blocking of this transcriptional network is an important determinant for the response to BYL719 in HNSCC.

[1]  P. Boutros,et al.  A controlled trial of HNSCC patient‐derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth , 2019, International journal of cancer.

[2]  J. Grandis,et al.  HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma , 2019, Scientific Reports.

[3]  K. Fung,et al.  ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. , 2018, Oral oncology.

[4]  R. Mehra,et al.  Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC) , 2018, Cancers of the Head & Neck.

[5]  Dejan Juric,et al.  Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Bicciato,et al.  MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state , 2017, Nature Communications.

[7]  N. Rajewsky,et al.  The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex , 2017, Genome Biology.

[8]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[9]  J. Humm,et al.  Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma , 2017, Nature Communications.

[10]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[11]  S. Bicciato,et al.  YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins , 2016, EMBO reports.

[12]  Gary D Bader,et al.  Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance , 2016, Cell.

[13]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[14]  C. Van Waes,et al.  The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. , 2015, Oral diseases.

[15]  G. Blandino,et al.  Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies , 2015 .

[16]  C. Lefebvre,et al.  Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. , 2015, Cancer cell.

[17]  S. Bicciato,et al.  Aerobic glycolysis tunes YAP/TAZ transcriptional activity , 2015, The EMBO journal.

[18]  Angela Tam,et al.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. , 2015, Cancer cell.

[19]  Olivier Lichtarge,et al.  Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. , 2015, Cancer research.

[20]  T. Serre,et al.  Reduced Expression of MYC Increases Longevity and Enhances Healthspan , 2015, Cell.

[21]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[22]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[23]  D. Felsher,et al.  MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.

[24]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[25]  E. Domany,et al.  Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Doriano Fabbro,et al.  Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. , 2013, Bioorganic & medicinal chemistry letters.

[27]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[28]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[29]  K. Ang,et al.  TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence , 2011, Clinical Cancer Research.

[30]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[31]  K. Vähäkangas,et al.  Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study , 2011, Head & neck oncology.

[32]  C. R. Leemans,et al.  Prognostic Significance of Truncating TP53 Mutations in Head and Neck Squamous Cell Carcinoma , 2011, Clinical Cancer Research.

[33]  I. Simon,et al.  Modulation of the vitamin D3 response by cancer-associated mutant p53. , 2010, Cancer cell.

[34]  P. Liu,et al.  c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[36]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[37]  E. Domany,et al.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis , 2009, Nature Structural &Molecular Biology.

[38]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[39]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[40]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[41]  J. Blenis,et al.  Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1 , 2008, Proceedings of the National Academy of Sciences.

[42]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[43]  V. Rotter,et al.  Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. , 2007, Cancer research.

[44]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[45]  C. Prives,et al.  Transcriptional regulation by p53: one protein, many possibilities , 2006, Cell Death and Differentiation.

[46]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[47]  R. Brentani,et al.  Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. , 2004, Cancer detection and prevention.

[48]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[49]  E. Schmidt,et al.  Activated eIF4E-binding Protein Slows G1 Progression and Blocks Transformation by c-myc without Inhibiting Cell Growth* , 2004, Journal of Biological Chemistry.

[50]  I. Mellinghoff,et al.  AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression* , 2004, Journal of Biological Chemistry.

[51]  M. Oren,et al.  Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities* , 2002, The Journal of Biological Chemistry.

[52]  J. Sedivy,et al.  A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. , 2001, Cancer research.

[53]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[54]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[55]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[56]  Brachman Dg,et al.  Molecular biology of head and neck cancer. , 1994, Seminars in oncology.

[57]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[58]  J. Moore,et al.  Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. , 1989, Oncogene.

[59]  Wei Zhao,et al.  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. , 2018, Cell systems.

[60]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[61]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.